The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study

Inclusion Criteria: 1. Children with pediatric lymphoma (HL and NHL) that met the criteria and required treatment upon histological and pathological diagnosis; 2. Age: \< 18 years old; 3. The working status of the Eastern Cooperative Oncology Group (ECOG) (PS) : 0-2 points; 4. CT/MRI measurable lesion was defined as the longest diameter of at least 1 lymph node ≥ 1.5cm, and it was clearly measurable in 2 vertical directions; 5. Complete clinical laboratory examination and pathological examination information; 6. Patients can be evaluated on time, and the required samples can be obtained throughout the testing process; 7. After the patient is informed of the project, the informed consent signed by the patient or his legal representative is obtained. Exclusion Criteria: * Patients with any of the following items will not be enrolled in this study: 1. Incomplete baseline samples (preoperative plasma samples, tissue, bone marrow, cerebrospinal fluid) due to various reasons; 2. The follow-up samples cannot be obtained during the monitoring process; 3. The researcher considered it unsuitable for enrollment.